A Plea For Patience: Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time
The cancer immunotherapy combo showed "remarkable" effects in patients who tested negative for PD-L1 expression and would normally not respond well to immunotherapy.
